Oxbow Advisors’s AstraZeneca AZN Stock Holding History

Oxbow Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8M	Buy	40,552 +1,408	+4%	+$271K	0.68%	38
2025 Q4	$7.2M	Buy	39,144 +347	+0.9%	+$60.9K	0.63%	40
2025 Q3	$5.95M	Buy	38,797 +19,021	+96%	+$2.88M	0.55%	48
2025 Q2	$2.76M	Buy	19,776 +722	+4%	+$101K	0.3%	82
2025 Q1	$2.8M	Buy	19,054 +382	+2%	+$55.3K	0.3%	73
2024 Q4	$2.45M	Buy	18,672 +17,193	+1,162%	+$2.41M	0.29%	82
2024 Q3	$230K	Buy	+1,479	New	+$239K	0.02%	187

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Oxbow Advisors's AZN Position: Q1 2026 in Review

Oxbow Advisors increased its AstraZeneca (AZN) stake by 3.6% in Q1 2026, buying an estimated $271K and bringing the position to 40,552 shares worth $8M. The position accounts for 0.68% of the portfolio, ranked #38.

Oxbow Advisors first reported a position in AZN in Q3 2024 and has held it in 7 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Oxbow Advisors held 40,552 shares of AstraZeneca worth $8M as of Q1 2026.
Oxbow Advisors bought 1,408 AstraZeneca shares in Q1 2026, an estimated $271K.
AstraZeneca made up 0.68% of Oxbow Advisors's portfolio in Q1 2026, its #38 holding.
Oxbow Advisors first reported a position in AstraZeneca in Q3 2024 and has held it in 7 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Oxbow Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.